UBS Group’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $107M | Buy |
401,881
+194,542
| +94% | +$45.4M | 0.01% | 1071 |
|
|
2026
Q1 | $47.4M | Sell |
207,339
-100,851
| -33% | -$22.6M | 0.01% | 1698 |
|
|
2025
Q4 | $65.7M | Buy |
308,190
+112,986
| +58% | +$23.3M | 0.01% | 1359 |
|
|
2025
Q3 | $38.8M | Buy |
195,204
+112,444
| +136% | +$21M | 0.01% | 1881 |
|
|
2025
Q2 | $14.3M | Sell |
82,760
-91,081
| -52% | -$14.8M | ﹤0.01% | 2727 |
|
|
2025
Q1 | $27.1M | Sell |
173,841
-51,846
| -23% | -$7.41M | 0.01% | 2055 |
|
|
2024
Q4 | $31.1M | Buy |
225,687
+213,262
| +1,716% | +$28M | 0.01% | 1891 |
|
|
2024
Q3 | $1.86M | Sell |
12,425
-3,496
| -22% | -$472K | ﹤0.01% | 4071 |
|
|
2024
Q2 | $2.17M | Sell |
15,921
-11,834
| -43% | -$1.61M | ﹤0.01% | 3692 |
|
|
2024
Q1 | $4.2M | Sell |
27,755
-172
| -0.6% | -$24.5K | ﹤0.01% | 3165 |
|
|
2023
Q4 | $3.52M | Sell |
27,927
-15,304
| -35% | -$1.53M | ﹤0.01% | 3155 |
|
|
2023
Q3 | $4.05M | Sell |
43,231
-556
| -1% | -$52K | ﹤0.01% | 2782 |
|
|
2023
Q2 | $3.91M | Buy |
43,787
+40,416
| +1,199% | +$3.52M | ﹤0.01% | 2823 |
|
|
2023
Q1 | $361K | Buy |
3,371
+751
| +29% | +$85.9K | ﹤0.01% | 4943 |
|
|
2022
Q4 | $320K | Sell |
2,620
-6,273
| -71% | -$728K | ﹤0.01% | 5062 |
|
|
2022
Q3 | $918K | Buy |
8,893
+7,376
| +486% | +$699K | ﹤0.01% | 3820 |
|
|
2022
Q2 | $141K | Sell |
1,517
-3,864
| -72% | -$364K | ﹤0.01% | 5170 |
|
|
2022
Q1 | $631K | Sell |
5,381
-1,000
| -16% | -$116K | ﹤0.01% | 4512 |
|
|
2021
Q4 | $859K | Sell |
6,381
-3,491
| -35% | -$519K | ﹤0.01% | 4528 |
|
|
2021
Q3 | $1.57M | Sell |
9,872
-1,162
| -11% | -$159K | ﹤0.01% | 3795 |
|
|
2021
Q2 | $1.45M | Buy |
11,034
+7,976
| +261% | +$1.06M | ﹤0.01% | 3863 |
|
|
2021
Q1 | $394K | Sell |
3,058
-208
| -6% | -$31.6K | ﹤0.01% | 5043 |
|
|
2020
Q4 | $545K | Sell |
3,266
-4,127
| -56% | -$682K | ﹤0.01% | 4537 |
|
|
2020
Q3 | $1.14M | Buy |
7,393
+3,751
| +103% | +$539K | ﹤0.01% | 3539 |
|
|
2020
Q2 | $538K | Sell |
3,642
-7,041
| -66% | -$967K | ﹤0.01% | 4068 |
|
|
2020
Q1 | $1.2M | Sell |
10,683
-3,220
| -23% | -$418K | ﹤0.01% | 3201 |
|
|
2019
Q4 | $1.93M | Buy |
13,903
+6,969
| +101% | +$774K | ﹤0.01% | 3572 |
|
|
2019
Q3 | $668K | Buy |
6,934
+770
| +12% | +$85.9K | ﹤0.01% | 4311 |
|
|
2019
Q2 | $710K | Buy |
6,164
+648
| +12% | +$77.5K | ﹤0.01% | 4020 |
|
|
2019
Q1 | $650K | Sell |
5,516
-1,617
| -23% | -$142K | ﹤0.01% | 3879 |
|
|
2018
Q4 | $447K | Sell |
7,133
-7,172
| -50% | -$451K | ﹤0.01% | 4352 |
|
|
2018
Q3 | $1.01M | Buy |
14,305
+4,592
| +47% | +$316K | ﹤0.01% | 3830 |
|
|
2018
Q2 | $646K | Buy |
9,713
+2,979
| +44% | +$196K | ﹤0.01% | 4125 |
|
|
2018
Q1 | $440K | Buy |
6,734
+2,670
| +66% | +$150K | ﹤0.01% | 4289 |
|
|
2017
Q4 | $163K | Buy |
4,064
+3,549
| +689% | +$129K | ﹤0.01% | 5055 |
|
|
2017
Q3 | $19K | Buy |
+515
| New | +$14.8K | ﹤0.01% | 6482 |
|
|
2017
Q2 | – | Sell |
-959
| Closed | -$27K | – | 7642 |
|
|
2017
Q1 | $27K | Buy |
959
+759
| +380% | +$19.2K | ﹤0.01% | 5928 |
|
|
2016
Q4 | $4K | Sell |
200
-718
| -78% | -$14.3K | ﹤0.01% | 7314 |
|
|
2016
Q3 | $18K | Buy |
+918
| New | +$15.2K | ﹤0.01% | 6373 |
|
|
2016
Q2 | – | Sell |
-1,417
| Closed | -$26K | – | 7702 |
|
|
2016
Q1 | $26K | Buy |
1,417
+13
| +0.9% | +$231 | ﹤0.01% | 6000 |
|
|
2015
Q4 | $26K | Buy |
+1,404
| New | +$24.6K | ﹤0.01% | 6457 |
|
|
2015
Q3 | – | Sell |
-788
| Closed | -$14K | – | 8391 |
|
|
2015
Q2 | $14K | Sell |
788
-77
| -9% | -$1.35K | ﹤0.01% | 7176 |
|
|
2015
Q1 | $15K | Buy |
+865
| New | +$15.7K | ﹤0.01% | 7274 |
|
Other funds holding ASND
RCM
ACA
JT
UBS Group's ASND Position: Q2 2026 in Review
UBS Group increased its Ascendis Pharma A/S (ASND) stake by 94% in Q2 2026, buying an estimated $45.4M and bringing the position to 401,881 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #1071.
UBS Group first reported a position in ASND in Q1 2015 and has held it in 43 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- UBS Group held 401,881 shares of Ascendis Pharma A/S worth $107M as of Q2 2026.
- UBS Group bought 194,542 Ascendis Pharma A/S shares in Q2 2026, an estimated $45.4M.
- Ascendis Pharma A/S made up 0.01% of UBS Group's portfolio in Q2 2026, its #1071 holding.
- UBS Group first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 43 quarters since.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.